Coya Therapeutics, Inc. (NASDAQ:COYA) Stock Has Average Price Target of $15.33 According to Brokerages

Shares of Coya Therapeutics, Inc. (NASDAQ:COYA) have earned a consensus recommendation of “Moderate Buy” from the seven analysts that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $15.33.

Several analysts have recently weighed in on COYA shares. HC Wainwright reaffirmed a “buy” rating on shares of Coya Therapeutics in a report on Friday, September 25th. Roth Capital restated a “buy” rating and issued a $12.00 price objective on shares of Coya Therapeutics in a research report on Monday, August 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Coya Therapeutics in a report on Thursday. Chardan Capital restated a “buy” rating and issued a $14.00 price target on shares of Coya Therapeutics in a research note on Wednesday, August 12th. Finally, BTIG Research reiterated a “buy” rating and issued a $16.00 price objective on shares of Coya Therapeutics in a research report on Tuesday, September 15th.

Coya Therapeutics Stock Down 2.1%

NASDAQ COYA traded down $0.09 during trading hours on Friday, hitting $4.25. 134,191 shares of the company were exchanged, compared to its average volume of 156,997. The company has a 50 day moving average of $4.76 and a two-hundred day moving average of $4.70. Coya Therapeutics has a 52-week low of $3.71 and a 52-week high of $7.55. The firm has a market cap of $99.70 million, a price-to-earnings ratio of -3.97 and a beta of 0.58.

Coya Therapeutics (NASDAQ:COYA) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.07. The firm had revenue of $0.24 million during the quarter, compared to the consensus estimate of $0.13 million. Coya Therapeutics had a negative return on equity of 52.05% and a negative net margin of 270.22%. On average, equities research analysts predict that Coya Therapeutics will post -1.34 EPS for the current year.

Institutional Trading of Coya Therapeutics

A number of institutional investors have recently added to or reduced their stakes in COYA. Cetera Investment Advisers grew its holdings in shares of Coya Therapeutics by 36.4% during the first quarter. Cetera Investment Advisers now owns 30,000 shares of the company’s stock worth $118,000 after buying an additional 8,000 shares in the last quarter. Allworth Financial LP boosted its position in Coya Therapeutics by 1,200.0% during the second quarter. Allworth Financial LP now owns 13,000 shares of the company’s stock worth $76,000 after acquiring an additional 12,000 shares during the last quarter. AXQ Capital LP acquired a new stake in Coya Therapeutics during the second quarter worth approximately $116,000. Renaissance Technologies LLC grew its stake in Coya Therapeutics by 55.4% in the 1st quarter. Renaissance Technologies LLC now owns 103,964 shares of the company’s stock worth $410,000 after acquiring an additional 37,064 shares during the period. Finally, Long Corridor Asset Management Ltd purchased a new stake in Coya Therapeutics in the 2nd quarter worth approximately $227,000. Hedge funds and other institutional investors own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies that regulate neuroinflammation and support immune-system function. The company’s research centers on regulatory T cells, or Tregs, immune cells that help control excessive inflammatory responses. Coya is developing treatments intended for neurodegenerative diseases in which inflammation may contribute to disease progression.

The company’s lead programs include COYA 101, an autologous Treg cell therapy in which a patient’s cells are collected, expanded and activated outside the body, and then administered as a potential treatment for amyotrophic lateral sclerosis (ALS).